Let-7 miRNA Nanoparticle Delivery for Endothelial Atherosclerosis Reversal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for atherosclerosis, such as statins, only slow the progression of the disease and do not stop or reverse it, and there is a lack of effective methods to inhibit or reverse the molecular events driving atherosclerosis progression.
Innovation Solution
A pharmaceutical composition comprising let-7 miRNA in a nanoparticle for selective delivery to endothelial cells, or agents that modulate the activity or level of TGFβ signaling polypeptides, to reduce or inhibit atherosclerotic lesions and progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statins are used to treat atherosclerosis, then the progression of the disease is slowed, but the disease cannot be stopped or reversed
Solution Approach 1:
The patent changes the therapeutic parameter from statin-based cholesterol lowering to miRNA-based gene expression modulation. Specifically, it uses let-7 miRNA or TGFβ signaling modulators to alter the molecular parameters of endothelial cell differentiation and smooth muscle cell phenotype, thereby achieving disease reversal rather than just progression slowing
Solution Approach 2:
The patent introduces miRNA molecules as intermediary substances that mediate the therapeutic effect. These miRNAs act as molecular mediators that regulate gene expression in endothelial cells and smooth muscle cells, enabling control over cell differentiation and phenotypic switching that statins cannot achieve
2Ease of operation
If conventional therapies are used, then treatment is simple and well-tolerated, but they lack the ability to inhibit molecular events driving atherosclerosis progression
Solution Approach 1:
The patent replaces the mechanical/pharmacological approach of statins (which work through protein synthesis inhibition) with a genetic regulatory approach using miRNA. This substitution targets the molecular events at their source by modulating gene expression patterns in endothelial and smooth muscle cells, providing more precise control over the pathological processes
Data Source
AI summary
In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGFβ signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell.